Eikon Therapeutics
Clinical trials sponsored by Eikon Therapeutics, explained in plain language.
-
New cancer drug trial tests immune system activation
Disease control CompletedThis early-stage study tested the safety and best dose of a new experimental drug called BDB001, which aims to activate the immune system to fight cancer. It was tested both alone and in combination with an existing immunotherapy drug (pembrolizumab) in 87 adults with advanced so…
Phase: PHASE1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New Immune-Boosting drug combo tested in advanced cancer patients
Disease control CompletedThis early-stage study tested the safety of an experimental immune-boosting drug called BDB001, given alone and combined with the immunotherapy drug atezolizumab (Tecentriq). It involved 40 adults with advanced solid tumors that had stopped responding to standard treatments. The …
Phase: PHASE1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New drug trial targets tough cancers that resist standard immunotherapy
Disease control CompletedThis study tested an experimental immunotherapy drug called BDB001 for people with advanced solid tumors that had stopped responding to standard immune checkpoint inhibitor treatments. The trial aimed to see if BDB001 could help control cancer growth and was safe for patients. It…
Phase: PHASE2 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New Immune-Boosting drug enters human testing for tough cancers
Disease control CompletedThis early-stage study tested a new drug called BDB001, which aims to activate the immune system to fight cancer. It was given to people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety and find the righ…
Phase: PHASE1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC